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Identifying Feasible Interventions to Prevent Long-term Health Consequences
of Psychotropic Medications Prescribed to Children at the Baird School
Arkhipova-Jenkins I1, Harris A1, Kleeman L1, Meyendorff A1, Victor J1, Winikor J1, Wright K1, and Kessler R1
1University

•Many children with behavioral needs
struggle in traditional classroom
settings. Children receive help
through specialized educational
institutions, pharmacotherapy, and
psychiatric counseling.
•While substantial information exists
about drug indications and side
effects, there is little literature
documenting the barriers caregivers
face in addressing side effects.
•Our group conducted a literature review to identify
the side effects and associated comorbidities of the
six most frequently prescribed psychotropic drugs
at the Baird School.
•We designed a survey to assess the caregivers’
resources and barriers to minimizing these side
31 surveys
effects, and then offered a collection of feasible
sent to
recommendations.
caretakers

•Our survey contained questions
about physical activity, nutrition,
sleep hygiene, medication
administration, access to
medical care and community/
state programs.
•Surveys were mailed to the
caretakers of the 31 students at
Baird School; responses were
collected for 2 weeks.
•Due to low initial survey
response, all 31 caretakers were
called to complete more surveys
by phone.
•Caretakers that were initially
unavailable were called a second
time. No messages were left.
12 surveys
returned to
Baird School

9 surveys
completed
via phone
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Figure 1:
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Figure 4: Amount of
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•Survey responses were tabulated
and data analysis was performed.

Figure 1: 56% (9/16) of respondents reported missed doses
of medication at least once per month.
Figure 2: There is a relationship between having a set
bedtime and less difficulty falling asleep.
Figure 3: 71% (12/17) of caregivers are not aware of specific
nutritional needs related to their children’s medications.
Figure 4: The CDC recommends 7 hours of physical activity
per week (60 minutes per day).
Figure 5: 71% (15/21) of children were reported to not be
involved in community programs offering physical activity;
caregivers cited a number of barriers.

•Survey data identified areas for health
improvement in Baird students.
•Baird students most often miss a dose of medication
because a caregiver forgot to administer it. Methods for
remembering when to give each dose may help reduce
adverse side effects associated with missing a dose.
•Since most children who experience sleep difficulties do not
have a bedtime routine, improving sleep hygiene may
improve overall health.
•Most caregivers were unaware of their children’s medicationspecific nutritional needs. Recommendations should promote
awareness about medications’ effects on appetite and activity.
•The majority of Baird students are not meeting the CDC
recommendations for physical activity.
•Behavioral problems are the most significant barrier to
involvement in community programs. Recommendations for
improving physical activity should include individual or
specialized forms of exercise.

•The sample size (31) & number of surveys completed (21)
were too small to reach statistical significance.
•Low initial survey response required follow-up phone calls,
but 15/31 caregivers were unreachable.
•Families with the greatest barriers may not have been
reached due to lack of access to phone/mail, lack of time or
motivation to complete the survey, or illiteracy.
•The current CDC recommendations for physical activity,
nutrition, & sleep are not specific to children taking
psychotropic medications.

•The most common drugs prescribed to students at the
Baird School include: Clonidine1, Riperidone2,
of Baird students are
3
4
5
Guanfacine , Lisdexamfetamine , Methylphenidate
NOT fulfilling the CDC’s
& Quetiapine6.
recommendations for physical activity
•These drugs are prescribed to treat various pediatric
conditions, including attention-deficit hyperactivity
Figure 5: Barriers to Participation in Community Programs
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•Studies suggest that these side effects can lead to
as well as identifying more accessible
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